These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26275354)

  • 1. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
    Heyborne KD; Allshouse AA; Carey JC
    Am J Obstet Gynecol; 2015 Dec; 213(6):844.e1-6. PubMed ID: 26275354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
    Co AL; Walker HC; Hade EM; Iams JD
    Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth.
    Heyborne KD; Allshouse AA
    Am J Perinatol; 2016 Oct; 33(12):1191-7. PubMed ID: 27464018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.
    Yee LM; Liu LY; Sakowicz A; Bolden JR; Miller ES
    Am J Obstet Gynecol; 2016 Mar; 214(3):374.e1-6. PubMed ID: 26829989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
    Combs CA; Garite TJ; Maurel K; Abril D; Das A; Clewell W; Heyborne K; How H; Huang W; Lewis D; Lu G; Miller H; Nageotte M; Porreco R; Sheikh A; Tran L;
    Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Obesity on the Rate of Recurrent Spontaneous Preterm Birth in Women Treated with 17-alpha Hydroxyprogesterone Caproate.
    Hauspurg A; Lemon LS; Serra AE; Sharma S; Venkataramanan R; Caritis SN
    Am J Perinatol; 2018 Jul; 35(9):809-814. PubMed ID: 29294501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
    Stringer EM; Vladutiu CJ; Manuck T; Verbiest S; Ollendorff A; Stringer JS; Menard MK
    Am J Obstet Gynecol; 2016 Jul; 215(1):105.e1-105.e12. PubMed ID: 26829508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort.
    Turitz AL; Bastek JA; Purisch SE; Elovitz MA; Levine LD
    Am J Obstet Gynecol; 2016 Apr; 214(4):536.e1-536.e5. PubMed ID: 26519784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate.
    Timofeev J; Feghali M; Boyle A; Istwan N; Rhea D; Driggers RW
    J Matern Fetal Neonatal Med; 2013 Jun; 26(9):881-4. PubMed ID: 23311766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.
    Furcron AE; Romero R; Plazyo O; Unkel R; Xu Y; Hassan SS; Chaemsaithong P; Mahajan A; Gomez-Lopez N
    Am J Obstet Gynecol; 2015 Dec; 213(6):846.e1-846.e19. PubMed ID: 26264823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: A randomized controlled trial.
    Pirjani R; Heidari R; Rahimi-Foroushani A; Bayesh S; Esmailzadeh A
    J Obstet Gynaecol Res; 2017 Jan; 43(1):57-64. PubMed ID: 27775195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth.
    Frey HA; Finneran MM; Hade EM; Waickman C; Lynch CD; Iams JD; Landon MB
    Am J Perinatol; 2023 Nov; 40(15):1695-1703. PubMed ID: 34905780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.
    Della Torre M; Enakpene C; Ravangard S; DiGiovanni L; Deyo K; Whelan A; Sutherland M; Fischer J
    Am J Obstet Gynecol MFM; 2019 Nov; 1(4):100051. PubMed ID: 33345841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
    Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
    Suresh S; Freedman A; Adams M; Hirsch E; Ernst LM
    Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.